![Daniel Menichella](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel Menichella
Chief Executive Officer at
INFINITOPES LIMITED
Profile
Daniel L.
Menichella is currently Chief Executive Officer & Director at Infinitopes Ltd. since 2026 and Director at Spybiotech Ltd. Former positions include Chief Executive Officer at CureVac SE from 2018 to 2020, President, Chief Executive Officer & Director at Kaleido Biosciences, Inc. from 2020 to 2022, Director at Paloma Pharmaceuticals, Inc., Vice President-Business Development at Merck KGaA from 2002 to 2007, Chief Business Officer at Zyngenia, Inc. from 2011 to 2013, Senior Vice President at MorphoSys AG, Senior Vice President-Business Development at Grifols Therapeutics, Inc. from 2007 to 2011, Chief Business Officer & Vice President at Beacon Therapeutics (USA), Inc. from 2013 to 2015, Senior Vice President-Business Development at Talecris Biotherapeutics Holdings Corp.
from 2007 to 2011, and Chief Business Officer at Bamboo Therapeutics, Inc. Education includes undergraduate studies at Harvard University and an MBA from The University of North Carolina at Charlotte.
Daniel Menichella active positions
| Companies | Position | Start |
|---|---|---|
Spybiotech Ltd.
 Spybiotech Ltd. BiotechnologyHealth Technology Develops a molecular superglue which it believes can be used to create vaccines | Director/Board Member | - |
INFINITOPES LIMITED
 INFINITOPES LIMITED Pharmaceuticals: MajorHealth Technology Develops vaccines for the treatment of cancer | Chief Executive Officer | 2026-05-11 |
Former positions of Daniel Menichella
| Companies | Position | End |
|---|---|---|
| KALEIDO BIOSCIENCES, INC. | Chief Executive Officer | 2022-04-07 |
CureVac SE
 CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Chief Executive Officer | 2020-03-10 |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 2015-01-27 |
Zyngenia, Inc.
 Zyngenia, Inc. Drugstore ChainsRetail Trade Develops new class of biotherapeutics | Corporate Officer/Principal | - |
Grifols Therapeutics, Inc.
 Grifols Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutic products | Corporate Officer/Principal | 2011-08-31 |
Training of Daniel Menichella
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
46
1st degree connections
14
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 14 |
|---|---|
Merck KGaA
 Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
Paloma Pharmaceuticals, Inc.
 Paloma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs and related products | Health Technology |
CureVac SE
CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Health Technology |
Zyngenia, Inc.
Zyngenia, Inc. Drugstore ChainsRetail Trade Develops new class of biotherapeutics | Retail Trade |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MorphoSys AG
 MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
Grifols Therapeutics, Inc.
Grifols Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutic products | Health Technology |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical research and development company that provides gene therapy development & clinical research services | Health Technology |
Talecris Biotherapeutics Holdings Corp.
 Talecris Biotherapeutics Holdings Corp. BiotechnologyHealth Technology Develops and markets plasma-derived protein therapy products | Health Technology |
The University of North Carolina at Charlotte
 The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops gene therapies for rare neuromuscular and central nervous system diseases | Health Technology |
Kaleido Biosciences, Inc.
 Kaleido Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company which develops therapeutic products to systematically shape the micro biome | Health Technology |
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Develops a molecular superglue which it believes can be used to create vaccines | Health Technology |
INFINITOPES LIMITED
INFINITOPES LIMITED Pharmaceuticals: MajorHealth Technology Develops vaccines for the treatment of cancer | Health Technology |
- Stock Market
- Insiders
- Daniel Menichella
